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Abstract
Objective: To assess the health related quality of life of patients with primary Sjögren's Syndrome
(PSS) in a large US sample.
Methods: Questionnaires were mailed to 547 patients with a confirmed diagnosis of PSS (PhysR-
PSS) and all active members of the Sjögren's Syndrome Foundation USA (SSF-PSS), half of whom
identified a friend without PSS to also complete the survey.
Results: 277 PhysR-PSS patients were compared to 606 controls. The mean age was 62 years in
the PhysR-PSS group and 61 years in the control group. 90% in both groups were women. Time
from first symptom to diagnosis of PSS was a mean of 7 years. Sicca related morbidity, fatigue
severity, depression and pain (assessed by validated questionnaires, PROFAD-SSI, FACIT-F, CES-
D, BPI) were significantly greater, and all eight SF-36 domains were significantly diminished, in
patients compared to controls. Somatic fatigue was the dominant predictor of physical function and
of general health. Depression was the dominant predictor of emotional well being. Health care
utilization was higher in patients than controls, including out of pocket dental expenses (mean:
PhysR-PSS = $1473.3, controls = $503.6), dental visits (mean: PhysR-PSS = 4.0, controls = 2.3),
current treatments (mean: PhysR-PSS = 6.6, controls = 2.5), and hospitalizations (53% PhysR-PSS,
vs. 40% controls).
Conclusion: Diminished health quality and excess health costs are prevalent among PSS patients.
Health experiences and functional impact of PSS is similar among US and European patients.
Delayed diagnosis, sicca related morbidity, fatigue, pain and depression are substantial suggesting
unmet health needs and the importance of earlier recognition of PSS.
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Primary Sjögren's syndrome (PSS) is a chronic, systemic
autoimmune disorder characterized by inflammation of
exocrine glands and functional impairment of the salivary
and lachrymal glands [1]. Females are affected nine times
more frequently than males. Previous European studies
have demonstrated significant reductions of health-
related quality of life in PSS patients, [2-8]. However,
despite the fact that PSS is a common disorder which sig-
nificantly impacts health status, the effect of PSS on a
broad spectrum of quality of life domains including eco-
nomic resources, work status, leisure activities and inter-
personnel relationships has not been well studied.
Because PSS is predominantly diagnosed in peri-meno-
pausal women, there is very limited data concerning the
health status of younger women particularly those of
child bearing age, as well as limited data concerning the
health status of men with PSS.
While earlier studies have concluded that PSS is a condi-
tion that affects patients physically, psychologically and
socially, the factors contributing to diminished health
quality in PSS are not well understood. A small study by
Sutcliffe demonstrated that with the exception of oral
damage, end organ damage was uncommon in primary
SS, yet the degree of functional disability was as great in
patients with primary SS as in those with SLE[3].
Strombeck investigated health related quality of life in 42
Swedish women with PSS[5]. All 8 scales of the SF-36 were
significantly decreased and the percentage of patients not
working due to disability was similar among patients with
PSS, RA and Fibromyalgia. PSS patients tended to score
worse on the psychological scales and experienced better
physical function than the RA patients, while the fibromy-
algia patients experienced lower levels of health quality
on all 8 SF-36 scales compared to both patients with RA
and PSS. To date, the relative effects of pervasive symp-
toms including fatigue, pain, psychological distress and
xerostomia on health quality are sparsely documented in
the PSS literature; hence the precise causes of diminished
functioning in PSS remain unclear.
A recent study of 111 patients with PSS by Champey
emphasized the importance of the psychological dimen-
sion on results of the SF-36. Fatigue and pain, but not dry-
ness, were correlated with both quality of life and
psychological distress[7]. There is limited and inconsist-
ent data regarding the impact of sicca symptoms on health
quality. Small sample size and differences in the assess-
ment instruments used make this data difficult to inter-
pret[9,10]. The present study was designed to address
these gaps in the PSS literature and to provide a systematic
investigation of the health experiences of a large cohort of
PSS patients in the United States. In order to provide a
comprehensive picture of the health status of PSS patients,
data was collected on multiple aspects of health quality
including resource utilization, out of pocket expenses,
and employment status as well as clinical manifestations.
Methods
Overview
Sjogren's patients were recruited through multiple sources
to create a representative sample. In addition to a physi-
cian-verified cohort of patients (our core sample), we also
created a large comparison group of Sjogren's patients for
cross-validation purposes by recruiting all active patient
members of the Sjogren's Syndrome Foundation (SSF).
'Healthy' controls were recruited through the SSF patients
through a process of peer nomination. Data were col-
lected through a mail survey between January 1 and July
31, 2007. Survey responses were anonymous. The study
received approval from the Western Institutional Review
Board (IRB), and where appropriate, the local IRB's with
which the referring physicians' clinics were associated.
Sample
PSS patients with a confirmed diagnosis according to the
2002 AECG criteria [11] were recruited through nine high-
volume clinics across the United States (referred to as
"PhysR-PSS"). To protect the patient's identity, the surveys
were sent to the physician offices for distribution among
eligible patients. We asked the nine physicians to identify
from their records all patients classified as having PSS
according to the 2002 AECG criteria. We asked physicians
who had 100 or fewer patients with PSS to recruit all eli-
gible patients for the survey. We asked physicians who
had more than 100 eligible patients to select 100 patients
at random and recruit them for the study. Subjects
recruited through the Sjogren's foundation (SSF-PSS)
were classified as "possible" PSS if they reported a diagno-
sis of Sjogren's syndrome and history of a positive minor
salivary gland biopsy and/or a positive anti-SSA/Ro or
anti-SSB/La test result. Questionnaires were also mailed to
all active patient members of the Sjögren's Syndrome
Foundation ("SSF-PSS"), half of whom were asked to
recruit a friend of the same age and gender and without a
diagnosis of SS to provide a community control group
("controls"). Patients were specifically instructed not to
recruit a relative. Subjects who self-reported a diagnosis of
a rheumatic co-morbidity (rheumatoid arthritis, systemic
lupus erythematosus, mixed connective tissue disease,
myositis or scleroderma) were eliminated from both the
patient and the control groups.
Questionnaire
We devised an extensive health questionnaire: the ASSESS
survey (Assessment of Symptoms and Experiences of Sjö-
gren's syndrome) for this study based on recommenda-
tions of a panel of Sjogren's investigators. The survey
included questions regarding co-morbid conditions and
previous health problems that were considered secondaryHealth and Quality of Life Outcomes 2009, 7:46 http://www.hqlo.com/content/7/1/46
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to or possibly associated with Sjogren's. A draft question-
naire was administered to 5 patients with Sjogren's syn-
drome and revisions were made based on their feedback.
No additional validation was undertaken. Key health
domains addressed included: frequency and severity of
symptoms, diagnostic timeline and path to diagnosis,
health conditions experienced, treatments used, provider
visits, hospitalizations within the past 5 years, dental visits
and costs of dental care as well as the overall impact of
Sjogren's on activity, family and social life. The ASSESS
questionnaire also included pre-validated instruments for
measurement of pain, fatigue, depression and cognitive
symptoms. Health related quality of life was assessed with
the Medical Outcomes Survey Short Form-36, (SF-
36)[12]; pain with the modified Brief Pain Inventory,
(BPI)[13]; fatigue with the Functional Assessment of
Chronic Illness Therapy, (FACIT-Fatigue)[14], and the
Profile of Fatigue and Discomfort-Sicca Symptoms Inven-
tory, (PROFAD-SSI)[8]; cognitive symptoms with the
Thinking scale[15] (for more details on this scale see
Additional file 1, Table S1); and, depressed mood with the
Center for Epidemiologic Studies Depression Scale(CES-
D) [16]. The PROFAD-SSI was also used to assess sicca
severity.
Description of the instruments used
The PROFAD-SSI is comprised of eight domain scores that
reflect different manifestations of fatigue and sicca. The
domain scores, including somatic and mental fatigue
domains, may be used independently or combined into a
composite fatigue score (ProF), or further summarized to
indices of fatigue and discomfort (PROFAD index) and
sicca severity (SSI index). PROFAD domain scores range
from 0 to 7 and PROFAD-SSI summary indices range from
0 to 28, with higher scores indicating worse functioning.
The BPI is scored into two measures – pain severity and
pain interference – that range from 0 to 10 with higher
scores indicating worse functioning. The Thinking scale is
a 6 item subjective cognitive index. It was developed as
part of a disease specific Lupus Qualtiy of life index and
while it has been shown to have good internal consistency
and test-retest reliability, [15] in a study of 121 subjects
with SLE, the index has not been previously validated in
primary Sjogren's. The Thinking scale provides a single
score that can range from 0 to 100 with higher scores rep-
resenting poorer functioning. The CES-D scale results in a
single score that can range from 0 to 60; a score greater
than 16 indicates depression, a score greater than 27 indi-
cates severe depression. The FACIT-F results in a single
score that can range from 0 to 52, with higher scores rep-
resenting better functioning. Each of the eight SF-36
domain scores – physical functioning, emotional well-
being, role limitations due to physical functioning/emo-
tional functioning, energy/fatigue, social functioning,
pain, and general health – can range from 0 to 100 with
higher scores representing better functioning.
Statistical Methods
Group comparisons
Univariate ANOVAs and 2-way chi-square tests were con-
ducted to assess the statistical significance of overall dif-
ferences between the various participant groups. ANOVAs
that were significant (p ≤ 0.05) and that entailed compar-
isons between three or more groups were followed up
with Fisher Least Significant Difference tests to determine
which groups were significantly different from one
another on the scale or item in question. Similarly, chi-
square tests that were significant (p ≤ 0.05) and that
entailed comparisons between three or more groups were
followed up with separate chi-square tests.
Regression Analyses
Linear regression analysis was used to investigate the con-
tribution of sicca symptom severity (SSI), somatic fatigue
(domain score from the PROFAD-SSI), mental fatigue
(domain score from the PROFAD-SSI), depression (CES-
D), pain severity (BPI) and cognitive symptoms (Thinking
scale) to quality of life, as defined by the physical func-
tioning, emotional well-being and general health SF-36
domains. Scale scores were used as predictors and age and
disease duration were used as covariates. For each depend-
ent variable, the analysis was run two ways, once with
each of the critical predictors (i.e. minus age and disease
duration) entered into their own regression equations,
and once with all of the critical predictors and covariates
entered into a single multivariate regression model. The
regression analyses were run for each of the two PSS
patient groups and for the controls. An effect was said to
be reliable if the parameter estimate for the associated pre-
dictor was significant by a 2-tailed t-test at p < .05.
Results
Of the 547 surveys sent to investigators' practices, 281
(51%) were returned completed. Four surveys were iden-
tified as duplicates and excluded; analyses were therefore
based on 277 PhysR-PSS patients. Of the 8, 694 surveys
mailed to SSF members, 3,939 (45%) were returned com-
pleted and of these 1,225 were classified as 'possible' PSS
according to the eligibility criteria. Since the diagnosis of
PSS could not be directly confirmed in the SSF patient
group, these data were not included in the analysis, how-
ever we found that the clinical characteristics and demo-
graphics were, in almost all respects similar, to the verified
PSS patients identified through the investigators' practices
and to previously reported referral based cohorts. It is of
interest therefore to compare the data from the large com-
munity based SSF patient sample to the investigator
referred sample and we have provided this analysis in theHealth and Quality of Life Outcomes 2009, 7:46 http://www.hqlo.com/content/7/1/46
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additional section (see Additional file 2, Tables S1 – S5).
630 surveys were received from non-SS controls. Of these,
24 were excluded from the control group as they had
reported a diagnosis of SS or another rheumatic condi-
tion, leaving 606 non-SS controls.
Demographic and Clinical Characteristics
Demographics and clinical characteristics of the patient
and control groups are displayed in Table 1. The mean
time from first symptom to diagnosis was 7 years for
PhysR-PSS patients. Ocular and oral dryness were the
most common presenting symptoms reported by 44%
and 39%, respectively, of PhysR patients; detailed data
regarding presenting symptoms has been described previ-
ously[17]. Key extra-glandular features such as Raynaud's,
purpura, lymph node swelling or pain, and leucopenia
were frequently experienced by PhysR-PSS patients. Mor-
bidity related to severe longstanding oral and ocular dry-
ness was significantly greater in patients compared to
controls (Table 1). The community-based SSF-PSS group
demonstrated similar data albeit with a slightly higher
female percentage (93%) and a lower frequency of vascu-
litis, CNS Sjögren's and Lymphoma than the PhysR-PSS
sample (see Additional file 2, Table S1).
The impact of Sjogren's syndrome on health related qual-
ity of life was substantial. PSS patients were more likely
than the non-SS adults to not be working due to disability
(Table 1). PhysR-PSS patients reported significant reduc-
tions in all eight domains of the SF-36 (Table 2). Addi-
tionally, pain, fatigue, depressed mood and cognitive
symptoms were significantly greater in patients compared
to controls. Depression (CES-D = 16) was present in 37%
of patients compared to 12% of controls. In order to
assess the impact of gender and disability, and due to the
small samples of men and work disabled in the PhysR
patient group, the PhysR and SSF patients were combined
in analyses comparing men with women and the work
disabled with the employed (see Additional file 2, Table
S3). Gender did not have a statistically significant effect
on any of the psychometric ratings. Patients who were
unemployed due to disability reported significantly more
pain, depression and cognitive dysfunction than those
who were employed (all p values < 0.05).
Health Care Utilization
Health care utilization among PSS patients was high. PSS
patients were significantly more likely than controls to
have been hospitalized in the past 5 years (PhysR-PSS =
Table 1: Patient profile: Demographics and clinical features
Demographics and Clinical Characteristics PhysR-PSS Controls
N = 277 N = 606
Age (Mean ± S.D.) 62 ± 12.6 61 ± 12.2
Gender (% Female) 90% 92%
Employment Status
Employed (net) 38% 49% (1,2)
Not Employed (due to disability) 12%* 0%
Disease Duration (Mean ± S.D.) 9.0 ± 8.4 N/A
Time from first symptom to diagnosis (Mean ± S.D.) 7.1 ± 9.4 N/A
Extra-glandular Symptoms
Raynaud's 51%* 14%
Forgetfulness 67% 62%
Depression (reported by patient) 54%* 41%
Lymph node pain or swelling 41%* 12%
Muscle pain 60%* 42%
Joint pain 78%* 52%
Neuropathy ("pins and needles," tingling and/or numbness in extremities) 70%* 41%
Extra-glandular Conditions
Purpura/petechia 14%* 4%
Vasculitis 17%* 2%
CNS Sjögren's 22%* 1%
Leucopenia 21%* 5%
Lymphoma 12%* 2%
Lung Disease 16%* 6%
Ocular Sicca-related Disorders
Chronic blepharitis 30%* 5%
Corneal scarring 18%* 2%
* p < .05.Health and Quality of Life Outcomes 2009, 7:46 http://www.hqlo.com/content/7/1/46
Page 5 of 9
(page number not for citation purposes)
53%, controls = 40%, p < 0.05). They experienced more
frequent infections, including urinary tract (PhysR-PSS =
44%, controls = 37%, p < 0.05), pneumonia (PhysR-PSS =
32%, controls = 23%, p < 0.05), and vaginal infections
(PhysR-PSS = 38%, controls = 29%, p < 0.05). Differences
in health care provider visits were largely accounted for by
visits to a rheumatologist (PhysR-PSS = 94%, controls =
13%, p < 0.05), ophthalmologist (PhysR-PSS = 79%, con-
trols = 51%, p < 0.05) or a neurologist (PhysR-PSS = 49%,
controls = 16%, p < 0.05). PSS patients were also more
likely than controls to use multiple medications (mean
number of medications both prescription and over the
counter medications) currently taken: PhysR-PSS = 6.7,
controls = 2.5, p < 0.05). Out-of-pocket spending for den-
tal care was two to three fold higher in the patient group
compared to the peer group (mean out-of-pocket spend-
ing in the past year: Phys R-PSS = $1473.30; controls =
$503.60, p < 0.05.
Predictors of Health-Related Quality of Life
Respondents were asked to rate the impact of SS (or their
"health" if non-SS controls) on various aspects of their life
on four point scales, where 1 indicated no impact and 4
indicated a major impact. Patients reported a greater
impact on multiple aspects of their lives than controls,
including physical activity (PhysR-PSS = 2.6, controls =
1.8, p < 0.05), intimacy (PhysR-PSS = 2.5, controls = 1.5,
p < 0.05), career (PhysR-PSS = 2.3, controls = 1.3, p <
0.05), daily activities (PhysR-PSS = 2.4, controls = 1.4, p <
0.05), social interactions (PhysR-PSS = 2.1, controls = 1.3,
p < 0.05) and mental alertness (PhysR-PSS = 2.2, controls
= 1.3, p < 0.05). Patients with more severe sicca symptoms
reported significantly greater impact of Sjogren's syn-
drome on all activities (Figure 1).
The results of the multivariate regression analysis are
shown in Table 3. Among the PhysR-PSS, sicca severity
and disease duration were not significant contributors to
impaired quality of life in any of the full models (with age
and disease duration taken into account). Somatic fatigue
was the only unique predictor of general health; pain
severity and depression were the only unique predictors of
emotional well-being, and physical functioning was pre-
dicted by age, pain severity and somatic fatigue. For emo-
tional well-being, the dominant unique predictor of
quality of life was depression, accounting on its own for
25% of the variance in the index among the PhysR-PSS
patients. The contributions of both depression and fatigue
are substantial and contribute uniquely to various aspects
of disability.
PROFAD-SSI
We and others have previously carried out validation of
this questionnaire in European patients with PSS, RA and
SLE [5,18,19] but not in the USA. As indicated in Figure 2,
the PROFAD-SSI distinguished between patients and con-
trols on all domains of the scale: PSS patients reported
more somatic fatigue, mental fatigue, arthritic symptoms,
uncomfortably cold hands, oral dryness, ocular dryness,
cutaneous dryness and vaginal dryness, all ts > 12.0, all ps
< 0.001. Similar data was obtained using the summary
PROF, PROFAD and SSI indices. Principal component
analysis was used to investigate the internal structure of
the PROFAD-SSI. Facet scores rather than individual items
were used for ease of interpretation and presentation but
gave similar results individual items (see Additional file 3,
Tables S1 – S3). Aggregation of the individual PROFAD
items into facet scores was supported by reliability analy-
ses, which showed each of the facets to be highly consist-
ent internally (range of Cronbach's alpha values: 0.74 to
0.97).
Discussion
This is the first study to investigate health status in a large
cohort of PSS patients in the US and is the most compre-
hensive description to date of the burden of illness expe-
rienced by PSS patients. We documented reduced
functioning among PSS patients in every domain of the
SF-36, and increased utilization of health care services
including medications, hospitalization rates, provider vis-
its and out- of pocket expenses. Compared to their peer
controls, PSS patients also reported greater work disabil-
ity.
Table 2: Severity/Impact of disease
Scores on Prevalidated Instruments PhysR-PSS Controls
N = 277 N = 606
SF-36$
Physical Functioning 61.1 81.1 *
Role limitations – Physical 35.0 78.0 *
Role limitations – Emotional 58.1 86.3 *
Energy/Fatigue 38.9 62.2 *
Emotional Well-being 69.4 78.5 *
Social Functioning 65.2 87.6 *
Pain 53.4 77.0 *
General Health 45.5 72.6 *
PROFAD – SSI@
PROF 5.3 * 1.9
PROFAD 10.1 * 3.6
SSI 11.7* 3.0
FACIT – Fatigue$ 30.1 43.0*
Modified BPI-SF@
Pain Severity 3.9* 1.5
Pain Interference 3.3 * 1.0
CESD@ 14.9 * 7.7
Thinking@ 30.1 * 16.4
$ Higher scores indicate better functioning; @ Higher scores indicate 
worse functioning
* p < .05.Health and Quality of Life Outcomes 2009, 7:46 http://www.hqlo.com/content/7/1/46
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Table 3: Multiple linear regression model of health quality in PSS patients and controls
SF-36 Domain Dependent Variable
Predictor Physical Functioning Emotional Well-Being General Health
R2 β SE R2 β SE R2 β SE
PhysR-PSS Patients (n = 201):
Sicca severity (domain from SSI) 0.01 0.09 0.32 0.00 0.03 0.19 0.00 -0.06 0.23
Somatic fatigue (domain from PROFAD-SSI) 0.07 -0.52*** 1.44 0.01 -0.17 0.87 0.08 -0.54*** 1.05
Mental fatigue (domain from PROFAD-SSI) 0.00 -0.03 1.34 0.00 -0.03 0.81 0.00 -0.03 0.98
Depression (CES-D) 0.00 0.01 0.19 0.25 -0.72*** 0.11 0.01 -0.12 0.14
Pain severity (domain from BPI) 0.04 -0.28*** 0.83 0.02 0.18** 0.50 0.00 -0.07 0.60
Age 0.05 -0.25*** 0.13 0.00 0.05 0.08 0.01 0.09 0.10
Duration of disease 0.00 -0.04 0.20 0.00 0.04 0.12 0.00 -0.02 0.14
Controls (n = 498):
Sicca severity (domain from SSI) 0.00 0.09* 0.28 0.00 -0.01 0.18 0.01 -0.10* 0.24
Somatic fatigue (domain from PROFAD-SSI) 0.05 -0.37*** 0.98 0.00 0.00 0.63 0.08 -0.46*** 0.85
Mental fatigue (domain from PROFAD-SSI) 0.00 0.08 0.90 0.00 -0.07 0.58 0.01 0.13* 0.79
Depression (CES-D) 0.00 0.01 0.12 0.25 -0.65*** 0.08 0.01 -0.13** 0.10
Pain severity (domain from BPI) 0.08 -0.35*** 0.52 0.00 -0.02 0.34 0.01 -0.15*** 0.46
Age 0.11 -0.34*** 0.06 0.04 0.19*** 0.04 0.00 -0.05 0.05
Note: The R-square values for the individual predictors are the incremental R-squares.
Note: All coefficients marked with one or more asterisks are significant by a two-tailed t-test.
* p < .05; ** p < .01; *** p < .001.
The comparison to age and gender-matched controls sug-
gests that the symptoms experienced by PSS patients are
related to the disease and not attributable to natural proc-
esses of aging. Our data demonstrates that the reduction
in health-related quality of life in PSS is similar to that
experienced by patients with RA and SLE[3,5,20]. The
reduction in quality of life experienced by PSS patients in
our cohort is highlighted by comparison of the fatigue
score, as measured by the FACIT-F, and the physical func-
tion component score of the SF-36 to that recently
reported in a large cohort of Rheumatoid Arthritis patients
with active disease who had failed anti-TNF therapy[21]
The FACIT-F of 30.33 and the SF-36 role limitations, phys-
ical = 30.9 reported in the active RA group are strikingly
similar to the scores of 30.1(FACIT-F) and 35.0 (SF-36
role limitations, physical) in our PSS cohort.
The characteristics of the patient population in terms of
mean age, gender and duration of symptoms were similar
to that previously reported in European PSS cohorts
[7,22]. The mean time to diagnosis of 7 years in our
patients is not unusual for PSS possibly due to the non-
specific nature of the presenting symptoms or to poor
physician awareness of PSS in general and confirms that,
despite a growing quantity of research regarding the sever-
ity of sicca symptoms and range of extra-glandular mani-
festations, recognition of the diagnosis is typically delayed
for many years after the onset of sicca symptoms. Moreo-
ver, while we recognize the limitations of self-reported
data, the patients identified by experienced physician
investigators in this study as meeting current American
European Consensus Criteria for diagnosis gave highly
similar information in almost every category including
rates of ocular and oral complications, key extra-glandular
features such as Raynaud's, joint swelling, purpura, lung
disease, and lymphoma to that previously reported in
European cohorts[6,23]. The validity of this sample is
supported by the expected prevalence of dry eye and dry
mouth, cardinal features of the disorder which are highly
predictive of the diagnosis. The generalizability of the
findings in the PhysR-PSS group is additionally supported
by the highly similar parallel health data provided by the
larger SSF-PSS group (see Additional file 2, Table S1 – S5).
Impact of SS among patients with low and high sicca severity Figure 1
Impact of SS among patients with low and high sicca 
severity.
Note: Mean score and Standard Errors for ratings of impact on various aspects of lifeHealth and Quality of Life Outcomes 2009, 7:46 http://www.hqlo.com/content/7/1/46
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Morbidity related to sicca symptoms was high. On both
the SF-36 and in the impact questions, patients with
greater sicca severity did report poorer functioning (see
Additional file 2, Table S1 – S5). However, sicca severity
did not contribute uniquely to health quality in any of the
multivariate models.
Cultural differences between countries do not appear to
contribute to health quality among patients with PSS. The
functional impact of PSS in our patients is similar to that
previously reported in European cohorts[4,5,7,8] Subjec-
tive memory loss and concentration difficulties are com-
monly reported by PSS patients but do not contribute to
disability independently of depression.
The relatively high rate of psychological and cognitive
symptoms reported by patients in our cohort is consistent
with data in the literature suggesting an increase in affec-
tive disorders in PSS [24-27]. Our data on the prevalence
of depression in PSS is consistent with that of previous
studies. Valtysdottir measured psychological status in a
Swedish cohort (N = 67) of PSS patients and reported that
possible depression was present in 30%, that 42% experi-
enced symptoms of anxiety and 60–70% reported cogni-
tive dysfunction[28]. In another study, by the same group
of investigators, it was also concluded that patients with
PSS have more psychiatric symptoms and lower sense of
well-being than patients with RA [29]. Despite somewhat
different case selection criteria and use of different instru-
ments, similar findings of increased psychological distress
in SS have been a consistent finding between countries
and among different cultural groups [30-34]
While the PSS subjects reported significantly greater
depression and cognitive symptoms than controls, mental
fatigue (memory problems and difficulty concentrating)
was not a unique predictor in any of the multivariate
models. The relationship between the depression fre-
quently encountered in PSS patients and cognitive impair-
ment is not well understood. Fatigue and depression,
along with pain, anxiety and sleep impairment can lead to
abnormal cognition. It is also the case that patients with
depression over estimate the degree of cognitive dysfunc-
tion they are experiencing[35]. More data is needed on the
relationship between subjective cognitive function and
cognitive performance in SS patients. It is possible that
depression and cognitive impairment are independent
but overlapping manifestations of central nervous system
disorder in SS patients. A recent community based
study[36] in which SLE patients were compared to those
with Primary Sjogren's syndrome found similar rates of
headaches (87% vs.78%), cognitive dysfunction 46% vs.
50%) and mood disorders (26% vs 33%). The lower inci-
dence of CNS Sjogren's (14–22%) reported by partici-
pants in this survey suggests that the common complaints
of headache, depression and symptoms of cognitive dys-
function are not usually diagnosed as CNS Sjogren's.
Patients who reported work disability also reported more
frequent cognitive symptoms, as well as fatigue, pain and
depression. However, factors predictive of work disability
have not been examined previously in PSS, and it is
unknown whether cognitive impairment contributes to
work disability as has been shown previously in systemic
lupus[37].
Our study design does have limitations pertaining to sam-
pling methodology. No information was available from
non-responders nor could non responders be recontacted
as data was collected anonymously. However, the
response rate of 50% among the patient samples is con-
sidered excellent for blind mailed surveys. Reliance on
self-report data is also a weakness of this study however in
general, all demographic and clinical data are in agree-
ment with earlier findings. Further research is needed to
confirm the impact of PSS on health resources and
employment suggested by our data.
In summary, this survey of the health experiences reported
by PSS subjects suggests a large unmet health burden.
Delays in the diagnosis of Sjogren's syndrome may con-
tribute to the psychological distress of unexplained symp-
toms and prevent the timely application of symptomatic
therapies that are effective in preventing sicca related com-
plications. Earlier diagnosis could potentially reduce mor-
bidity attributable to sicca complications such as corneal
scarring and tooth loss. Improved understanding of the
neurobiology of pain and fatigue, as well as greater appre-
ciation of the pervasive effects and reduced quality of life
experienced by patients with PSS, is needed to reduce the
health care costs and ultimately the burden of illness expe-
rienced by those with PSS.
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